Pharmaceuticals company Ami Organics announced Q4FY24 & FY24 results: Revenue from operations for Q4FY24 grew by 20.7% YoY and 35.2% QoQ to Rs 2,250 million The gross margin for the quarter was at 40.0%. Gross margins were impacted due to change in product mix. EBITDA for the quarter came at Rs 432 million up 5.9% YoY compared to Rs 408 million in Q4FY23 and up 62.8% QoQ compared to Rs 265 million in Q3FY24. EBITDA margin for the quarter was at 19.2% as compared to 21.9% in Q4FY23 and 15.9% in Q3FY24. EBITDA margins contracted by 269bps YoY and grew by 326 bps sequentially. Adjusted PAT for the quarter was Rs 260 million. Adjusted PAT margin for the quarter was 11.6%. Commenting on results, Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am pleased to share that we have been successful in navigating through the tough industry scenario to deliver an all-time high quarterly revenue from operations of Rs 225 crore. This represents a growth of 21% YoY and an exceptional 35% sequential growth. Our advanced pharmaceuticals business, grew strongly by 18% YoY and 47% QoQ while our specialty chemicals business grew robustly by 36% YoY during the quarter. I am delighted to share that we have achieved the 'Gold Medal' accreditation from EcoVadis. Although we are in chemicals manufacturing industry, we remain steadfast on our sustainability goals propelled by an intensified focus on green chemistry and green initiatives. This commitment underscores our proactive approach to environmental responsibility and sustainability. I am also thrilled to inform you that recently we have received grant of 3 process patents from The Patent Office, Government of India. Two of these three products are niche and complex in nature. Overall, I believe that we have navigated industry challenges adeptly in FY24 and as we progress ahead with improved overall prospects for the industry, we firmly believe we will sustain our growth trajectory, targeting a revenue growth in range of 20-25% for the fiscal year FY25.” Result PDF
Conference Call with Ami Organics Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceutical company Ami Organics announced Q3FY24 results: Financial Highlights for Q3FY24: Revenue from operations for Q3FY24 grew by 9.2% YoY to Rs 1,664 million. The gross margin for the quarter was at 42.9% as compared to 46% in Q3FY23 and 41% in Q2FY24. Gross margins contracted 303 basis points YoY but expanded by 190 bps sequentially. Gross margins were driven by unfavourable product mix and pricing pressure. EBITDA for the quarter came at Rs 265 million, down 13.9% YoY compared to Rs 308 million in Q3FY23 and up 6.8% QoQ compared to Rs 248 million in Q2FY24. EBITDA margin for the quarter was at 15.9% as compared to 20.2% in Q3FY23 and 14.4% in Q2FY24. EBITDA margins degrew by 430bps YoY and grew by 153 bps sequentially. EBITDA margins were largely driven by gross margins. PAT for the quarter was Rs 178 million. The PAT margin for the quarter was 10.7% Commenting on the results, Mr. Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited, said, “In the face of a challenging landscape of the chemical industry, I am pleased to report that we have been able to deliver quality growth in Q3FY23 with our revenue from operations growing 9.2% YoY to Rs. 1,664million. This growth is underpinned by robust volume growth of 25%, indicating strong business traction. During the quarter, we further solidified our relationship with Fermion by signing an agreement for two additional advanced intermediates for their APIs. This milestone reflects AMI Organics’ prowess in fostering enduring client relationships, ably supported by strong R&D; and manufacturing strengths. Additionally, we also inaugurated a state-of-the-art, technology-driven plant at our Ankleshwar site, designed to meet the growing demand in the pharmaceutical intermediate business. I am also excited to share that we have signed an MOU with a global manufacturer of electrolytes for the manufacturing of electrolytes for battery cells and allied materials. In this context, we have also signed an MoU with the Government of Gujarat for investment amounting up to Rs 300 crores for setting up of a dedicated manufacturing facility for electrolytes business in Gujarat. Despite the industry headwinds, we remain confident of closing the year with healthy growth. I would also like to highlight that the various initiatives we have taken in FY23 and FY24 enhances our revenue visibility for FY25 and beyond, bolstering our confidence in our potential for stronger growth in coming years.” Result PDF